RECRUITING

Safety and Immunogenicity Study of Revaccination With SCB-1019T in Healthy Adults

Description

CLO-SCB-1019-002 is the first study of SCB-1019T vaccine for revaccination in older adults who were previously vaccinated with AREXVY. The safety, tolerability and immunogenicity of SCB-1019T are assessed.

Conditions

Study Overview

Study Details

Study overview

CLO-SCB-1019-002 is the first study of SCB-1019T vaccine for revaccination in older adults who were previously vaccinated with AREXVY. The safety, tolerability and immunogenicity of SCB-1019T are assessed.

A Phase 1, Placebo-controlled, Randomized, Observer-blind Study to Describe the Safety, Tolerability and Immunogenicity of SCB-1019T in Adults Who Were Vaccinated With AREXVY at Least 18 Months Before

Safety and Immunogenicity Study of Revaccination With SCB-1019T in Healthy Adults

Condition
RSV Infection
Intervention / Treatment

-

Contacts and Locations

Knoxville

Knoxville, Knoxville, Tennessee, United States, 37909

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Male and female participants 60-85 years of age at the screening visit and who received AREXVY before.
  • 2. Individuals are willing and able to comply with study requirements, including all scheduled visits, vaccination, laboratory tests, and other study procedures.
  • 3. Individuals willing and able to give an informed consent, prior to screening.
  • 4. Healthy participants as determined by medical history, physical examination, and clinical judgment of the investigator; participants with pre-existing stable medical conditions can be included (a stable medical condition is defined as a disease not requiring significant change in therapy or hospitalization for worsening disease during the 3 months before enrollment).
  • 1. Acute disease or fever (≥38°C) at time of vaccination. Participants with a minor illness (mild diarrhea, mild upper respiratory infection) without fever may be enrolled at the discretion of the investigator. For participants with minor illness and/or fever at the time of vaccination, Visit 1 may be rescheduled within the allowed time-window.
  • 2. Recurrent or un-controlled neurological disorders or seizures.
  • 3. Serious or unstable chronic illnesses
  • 4. Any history of dementia or any medical condition that moderately or severely impairs cognition
  • 5. History of a severe adverse reaction associated with a vaccine or severe allergic reaction (e.g., anaphylaxis) to any component of the study vaccines.

Ages Eligible for Study

60 Years to 85 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Clover Biopharmaceuticals USA, LLC,

Study Record Dates

2026-06-03